Clinical trials: Major Depressive Disorder, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Major Depressive Disorder
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Major Depressive Disorder, Post Traumatic Stress Disorder
Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)
This observational registry aims to collect real-world data on ketamine use in psychiatric inpatients within a regional tertiary-reference center.
- Conditions
- Major Depressive Disorder, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder, Somatoform Disorders
- Trial name
- KetGD (NCT05565352)
- Testing
- Ketamine Hydrochloride
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Gdansk
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Intravenous Ketamine for Treatment-Resistant Depression
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA…
- Trial name
- G2K (NCT06668571)
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large…
- Trial name
- NCT05450432
- Testing
- Ketamine, Esketamine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Depression, Anxiety
Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression
A Dual-Center, Randomized, Controlled, Blinded, Prospective Study on the Effects of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients with Mild-to-Severe Depression
- Conditions
- Depression, Anxiety, S-ketamine, Breast Cancer
- Trial name
- NCT07374198
- Testing
- Esketamine 0.3mg/kg, normal saline
- Volunteers
- 142 people
- Sponsor
- Chinese PLA General Hospital
Depression
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
Background: Researchers developed [11C]MC1, a radioligand for cyclooxygenase-2 (COX-2). COX-2 is an enzyme induced in the brain during inflammation.
- Trial name
- NCT04582916
- Testing
- 11C-MCI, 11CPS13
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression Moderate, Major Depression Severe
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07748091
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major Depressive Disorder
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of…
- Conditions
- Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder
- Trial name
- NCT05786066
- Testing
- Perampanel 6 MG, Ketamine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Major Depressive Disorder, Treatment Resistant Depression
Ketamine Augmentation of ECT in Treatment-Resistant Depression
This is a randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating the additive effect of intravenous ketamine in combination with electroconvulsive therapy (ECT) in patients with treatment-resistant major…
- Trial name
- Ketamina (NCT07088380)
- Testing
- Ketamine Hydrochloride
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Università Vita-Salute San Raffaele
Healthy Volunteers, Depression
Neurobiology of Suicide
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.
- Trial name
- NCT02543983
- Testing
- Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)
To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions
- Trial name
- KET-DUAL (NCT07247370)
- Testing
- Ketamine, Cognitive Behavioural Therapy
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- South West Sydney Local Health District
Major Depressive Disorder
Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders
This project aims to evaluate a male-specific psychotherapeutic program (MSPP) for MDD based on cognitive behavioral therapy (CBT). The primary goal is to test the superiority of the MSPP.
- Trial name
- MSPP-MDD (NCT05435222)
- Testing
- Male-specific psychotherapeutic program (MSPP), Cognitive beahvioral therapy (CBT)
- Where
- Switzerland
- Volunteers
- 244 people
- Sponsor
- Andreas Walther
Major Depressive Disorder
Pharmacologic Treatment Augmentation in Chronic Depression
To enroll in this clinical trial, prospective participants must meet stringent criteria. The participants need to fall within the age range of 18 to 64 and exhibit chronic depression at therapy resistance stage 2.
- Trial name
- Ket+CBASP (NCT06410599)
- Testing
- Ketamine, CBASP, TAU
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Major Depressive Disorder (MDD)
Sedation and Guided Education for Depression Study
The goal of this clinical trial is to understand how patient education surrounding a one-time, consciousness-altering medical intervention impacts the antidepressant response to the intervention in adults with major depressive…
- Trial name
- SAGE (NCT06705270)
- Testing
- Response-focused education, Diagnosis-focused education, IV naloxone
- Volunteers
- 40 people
- Sponsor
- Stanford University
Suicidal Ideation, Major Depressive Disorder (MDD)
Understanding and Treating Suicidal Ideation With Ketamine
The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (MDD) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic…
- Trial name
- NCT06891300
- Testing
- ketamine hydrochloride
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- The Royal's Institute of Mental Health Research
Depression
Improvement of Depression With Use of ATP
This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the…
- Trial name
- NCT06266715
- Testing
- ATP Group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Major Depressive Disorder (MDD)
Precision Depression Adalimumab Trial
The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro…
- Trial name
- PDAT (NCT07845604)
- Testing
- Adalimumab Biosimilars Injection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Daniel Moriarity
Depression - Major Depressive Disorder, Alcohol Use Disorder
ACT_for Alcohol Use Disorder and Depression
Alcohol use disorders (AUDs) and depressive disorders frequently coexist, complicating the clinical management of patients suffering from them.
- Trial name
- NCT06620276
- Testing
- Acceptance and Commitment Therapy, Ketamine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)